Deerfield Provides $50MM Second Tranche of Convertible Credit Facility to ADC Therapeutics
ADC Therapeutics received the $50 million second tranche under its convertible credit facility with Deerfield Partners following the FDA approval of ZYNLONTA.
May 19, 2021
ADC Therapeutics | Chris Martin | Deerfield Partners
Phil Neuffer